Chlortetracycline hydrochloride suspension and its preparation method, storage method, diluent and dilution method

By using glycerol and propylene glycol as solvents and combining antioxidants, nano-grade olemycin hydrochloride suspension was prepared, which solved the stability of olemycin hydrochloride in water and organic solvents, and achieved drug stability and good quality at high temperatures The solubility of the group feeding drug delivery needs.

CN117860671BActive Publication Date: 2024-11-22SOUTH CHINA AGRICULTURAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410066840.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-01-17
Publication Date
2024-11-22
Estimated Expiration
2044-01-17

AI Technical Summary

Technical Problem

The poor stability of chlormycin hydrochloride in water and organic solvents leads to degradation of drug efficacy. The prior art has failed to effectively solve the stability and dispersion of insoluble drugs, and there is a lack of approved oral liquid preparations.

Method used

Using glycerol and/or propylene glycol as solvents, combined with antioxidants such as vitamin E, nanoscale olemycin hydrochloride suspensions are prepared by ultrasound and grinding to ensure the stability and arbitrary dilution of the drug at high temperatures.

Benefits of technology

The high temperature stability and good solubility of olemycin hydrochloride are achieved, the formation of inactive isomer compounds is reduced, the content of the main components of the drug is ensured, the bioavailability is improved, and group feeding is facilitated.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117860671B_ABST
    Figure CN117860671B_ABST
Patent Text Reader

Abstract

The present application belongs to the technical field of antibiotics, and discloses a chlortetracycline hydrochloride suspension, comprising chlortetracycline hydrochloride and a solvent; the solvent is glycerol and / or propylene glycol. The chlortetracycline hydrochloride suspension has the function of high temperature degradation resistance, can inhibit the opening of the chlortetracycline hydrochloride C ring and reduce the generation of inactive isomeric compounds, ensure that the content of the main component of the drug and the content of related substances are within the specified limits, and have good solubility. At the same time, the present invention also discloses a storage method, a diluent, and a dilution method of the chlortetracycline hydrochloride suspension.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of antibiotics, and in particular to a chlortetracycline hydrochloride suspension and a preparation method, a preservation method, a diluent and a dilution method thereof. Background Art

[0002] Chlortetracycline (CTC) belongs to the tetracycline antibiotics. It was developed by the American Cyanamid Company in 1949. It is a broad-spectrum tetracycline antibiotic. It binds to the 30S subunit of the bacterial ribosome and interferes with the synthesis of bacterial proteins, thereby inhibiting the growth and reproduction of bacteria. The U.S. Food and Drug Administration (FDA) has approved chlortetracycline hydrochloride for use in chickens, turkeys, pigs, calves, beef cattle and non-lactating dairy cows, etc., with a wide range of applications. Chlortetracycline has the advantages of a broad antibacterial spectrum, a short withdrawal period and a low price, and is particularly effective in controlling Mycoplasma synoviae.

[0003] Chlortetracycline hydrochloride soluble powder is the most common product on the market in China, while chlortetracycline skin spray, soluble powder and veterinary eye ointment can be found abroad. The chlortetracycline premix previously used on the market is a fully fermented product. Intensive farming mainly administers drugs through drinking water. Chlortetracycline is the most unstable drug among tetracycline antibiotics. In alkaline solutions, it is easy to decompose into dehydrates; in weakly acidic solutions, it is easy to undergo diastereoisomerization and transform into diastereoisomerization of chlortetracycline with no antibiotic activity, thus losing its efficacy. The existing chlortetracycline hydrochloride soluble powder is administered by dosing pumps, which is easy to remain in the pipeline. When used with other drugs, it is easily affected by the pH of the solution, resulting in drug degradation, and has poor stability in water. Therefore, it is crucial to improve the solubility and stability of the drug in water.

[0004] The preparation of suspensions of poorly soluble drugs can refer to the following scheme:

[0005] CN1500492A A veterinary suspension injection containing antiparasitic drugs, which uses benzyl benzoate or triacetin; or glycerol, propylene glycol, polyethylene glycol, glycerol formaldehyde as solvent, which needs to be used together with water, or two or more of them can be used in combination with water;

[0006] CN1572301A A veterinary injection containing tylosin antibiotics, which uses glycerol triacetate and benzyl benzoate. Formaldehyde glycerol, dimethylacetamide or N-methyl-pyrrolidone or non-ionic surfactant can also be added to the preparation. When preparing the suspension, a suspending agent can also be added.

[0007] The above composition only solves the problem of how to improve the suspension stability and dispersibility of the drug. The above drug may not be prone to decomposition / degradation, so the above solution is not concerned.

[0008] During the storage, transportation and use of chloramphenicol, chloramphenicol hydrochloride has extremely poor stability in water and its stability in organic solvents is also not ideal. Therefore, there is no approved or imported registered chloramphenicol oral liquid preparation on the market.

[0009] The problem that this scheme needs to solve is: how to develop a chlortetracycline hydrochloride nanosuspension that has high stability in water and organic solvents, can be diluted in any ratio, is evenly dispersed, and does not clog pipelines. Summary of the invention

[0010] The purpose of the present invention is to provide a chlortetracycline hydrochloride suspension, which has the function of resisting high temperature degradation, can inhibit the opening of the chlortetracycline hydrochloride C ring and reduce the generation of inactive isomeric compounds, ensures that the content of the main component of the drug and the content of related substances are within the specified limits, and has good solubility.

[0011] The chlortetracycline hydrochloride suspension of the present invention can be used in combination with a dosing pump to be diluted in any proportion, which is convenient for group feeding. In terms of chlortetracycline hydrochloride, when the content after dilution is not higher than 10 mg / mL, a clear and transparent golden yellow solution can be formed in water; when the content is higher than 10 mg / mL, it can be suspended in water in any proportion, the suspension can be further diluted and can be quickly dissolved in water, and has good stability within 2 hours.

[0012] At the same time, the invention also discloses a storage method and a dilution method of the chlortetracycline hydrochloride suspension.

[0013] To achieve the above object, the present application discloses a chlortetracycline hydrochloride suspension, comprising chlortetracycline hydrochloride and a solvent;

[0014] The solvent is glycerol and / or propylene glycol.

[0015] In the above-mentioned chlortetracycline hydrochloride suspension, the concentration of chlortetracycline hydrochloride in the suspension is 1 to 60 wt %.

[0016] In some embodiments of the present invention, the concentration of chlortetracycline hydrochloride in the suspension is 1wt%, 2wt%, 3wt%, 4wt%, 5wt%, 6wt%, 7wt%, 8wt%, 9wt%, 10wt%, 15wt%, 20wt%, 25wt%, 30wt%, 35wt%, 40wt%, 45wt%, 50wt%, 55wt% or 60wt%;

[0017] In the above-mentioned chlortetracycline hydrochloride suspension, the concentration of chlortetracycline hydrochloride in the suspension is 10 to 50 wt %.

[0018] In the above-mentioned chlortetracycline hydrochloride suspension, the solvent is a mixture of glycerol and propylene glycol;

[0019] The weight ratio of glycerol to propylene glycol in the solvent is 1-9:1-9.

[0020] In some embodiments of the present invention, the weight ratio of glycerol to propylene glycol is 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1 or 9:1;

[0021] In the above-mentioned chlortetracycline hydrochloride suspension, the weight ratio of glycerol to propylene glycol in the solvent is 1-4:1-4.

[0022] Preferably, an antioxidant is also added to the chlortetracycline hydrochloride suspension.

[0023] In the above-mentioned chlortetracycline hydrochloride suspension, the amount of the antioxidant is 0.001 to 1 wt %.

[0024] In some embodiments of the present invention, the amount of the antioxidant is 0.001wt%, 0.01wt%, 0.05wt%, 0.1wt%, 0.2wt%, 0.5wt% or 1wt%;

[0025] In the above-mentioned chlortetracycline hydrochloride suspension, the antioxidant is one or more of vitamin E, vitamin C, thioglycerol, 2,6-di-tert-butyl-p-cresol, and butylated hydroxyanisole.

[0026] At the same time, the present invention also discloses a method for preparing the chlortetracycline hydrochloride suspension as described above, which comprises putting the chlortetracycline hydrochloride raw material into a solvent, grinding and stirring.

[0027] In the above-mentioned preparation method of chlortetracycline hydrochloride suspension, the chlortetracycline hydrochloride raw material is put into a solvent, ultrasonicated, and then a grinding medium is added, stirred, and filtered. The optional grinding medium includes zirconium oxide beads, steel balls, and the like.

[0028] At the same time, the present invention also discloses a method for preserving chlortetracycline hydrochloride, wherein chlortetracycline hydrochloride is prepared into any of the above-mentioned chlortetracycline hydrochloride suspensions for preservation.

[0029] In the above-mentioned storage method, the storage temperature is 0 to 80°C.

[0030] In the above-mentioned storage method, the storage temperature is room temperature to 60°C.

[0031] Finally, the present invention also discloses a method for diluting chlortetracycline hydrochloride, which comprises dispersing any of the above chlortetracycline hydrochloride suspensions into water to obtain a diluted aqueous solution.

[0032] In the above dilution method, when the concentration of chlortetracycline hydrochloride in the diluted aqueous solution is 10 mg / mL, a uniform solution can be formed in water;

[0033] When the content of chlortetracycline hydrochloride in the diluted aqueous solution is higher than 10 mg / mL, the aqueous solution is further mixed with additional water in any ratio.

[0034] Meanwhile, the present invention also discloses a chlortetracycline hydrochloride diluent, which is prepared by dispersing any of the above-mentioned chlortetracycline hydrochloride suspensions into water in any proportion.

[0035] The beneficial effects of this application are:

[0036] The solvent of the suspension is a screened mixed organic system that can meet the requirements of the stability test, inhibit the opening of the C ring of chlortetracycline hydrochloride to reduce the generation of inactive isomeric compounds, ensure that the content of the main component of the drug and the content of related substances are within the specified limits, and have good solubility. The drug particle size can reach nanometer level, which can improve the bioavailability to a certain extent.

[0037] The suspension has a simple processing technology, can withstand high temperatures above 60°C, and can fully cope with high temperature storage environments in summer.

[0038] This suspension can be used with a dosing pump to dilute it in a certain ratio, which is convenient for group feeding. Calculated as chlortetracycline hydrochloride, when the content after dilution is not higher than 10 mg / mL, it can form a clear and transparent golden solution in water; when the content is higher than 10 mg / mL, it can be suspended in water at any ratio. The suspension can be further diluted and can be quickly dissolved in water, and has good stability within 2 hours. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figure 1 This is the chromatogram of chlortetracycline hydrochloride reference solution;

[0040] Figure 2 is the chromatogram of the reference solution;

[0041] Figure 3 The chromatogram of the reference solution (1) is shown below;

[0042] Figure 4 is the chromatogram of the test solution;

[0043] Figure 5 These are photos of chlortetracycline hydrochloride solutions of different dilutions of prescription 1 at 0h;

[0044] Figure 6 These are photos of chlortetracycline hydrochloride dilutions of different dilutions of prescription 1 at 2 hours;

[0045] Figure 7 This is a photo of the chlortetracycline hydrochloride dilution solution of 0.3g / L dilution concentration of prescription 2-10 at 0h;

[0046] Figure 8 This is a photo of the 0.3g / L dilution concentration of chloramphenicol hydrochloride of prescription 2-10 after 2 hours. DETAILED DESCRIPTION

[0047] The present invention will be described clearly and completely below in conjunction with the embodiments of the present invention. In the description of the present invention, it should be noted that, if no specific conditions are specified in the embodiments, the conditions are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0048] The suspension of the present invention can be prepared by conventional methods, that is, mixing, grinding and dispersing can meet the purpose of stable dispersion.

[0049] In the embodiments of the present invention, the following process is uniformly adopted for preparation:

[0050] At room temperature, chlortetracycline hydrochloride raw material was put into the mixed solvent, ultrasonicated for 30 minutes, zirconium oxide beads (particle size 0.3 mm) in an amount equal to the solvent were added, stirred for 3 hours using an electric stirrer with a double-blade PTFE rod, the zirconium oxide beads were filtered out with a suction filtration device, and the mixture was filled, nitrogen-filled, and packaged.

[0051] It should be noted that even if ultrasound and grinding are not used in the present invention, as long as the particle size of the chlortetracycline hydrochloride raw material is fine, it can be stably suspended in the solvent.

[0052] The present invention is divided into two parts to verify the performance of the relevant solvents of the present invention. The first part is the storage performance at 40°C, and the second part is the storage performance at 60°C. The performance at temperatures lower than 40°C is not listed. At lower temperatures, the degradation rate of chloramphenicol hydrochloride is lower, so it will not be discussed additionally.

[0053] The detection methods of the following substances are as follows:

[0054] Method basis: Refer to the chromatographic conditions and determination methods under the quality standard of chlortetracycline hydrochloride in the "Chinese Veterinary Pharmacopoeia (2020 Edition)" and the "Guidelines for Validation of Analytical Methods for Veterinary Drug Quality Standards". The chromatographic conditions for content determination are the same as those for related substances.

[0055] Chromatographic conditions:

[0056] Column: Kromasil 100-5-C8 (4.6×150nm)

[0057] Mobile phase: perchloric acid-dimethyl sulfoxide-water (8:525:467) (pH < 2.0)

[0058] Detection wavelength: 280nm

[0059] Column temperature: 45°C

[0060] Flow rate: 1mL / min

[0061] Injection volume: 20 μL

[0062] Determination method: Take the product, accurately weigh it, add 0.01mol / L hydrochloric acid solution to dissolve it and quantitatively dilute it to make a solution containing 1.0mg per 1mL as the test solution; take chlortetracycline hydrochloride reference substance, accurately weigh it, add 0.01mol / L hydrochloric acid solution to dissolve it and quantitatively dilute it to make a solution containing 1.0mg per 1mL as the chlortetracycline hydrochloride reference substance solution.

[0063] The relevant substances are freshly prepared for clinical use. Take this product, accurately weigh it, add 0.01mol / L hydrochloric acid solution to dissolve it and quantitatively dilute it to make a solution containing 1.0mg per 1mL as the test solution; take tetracycline hydrochloride reference substance and 4-chlortetracycline reference substance, accurately weigh it, add 0.01mol / L hydrochloric acid solution to dissolve it and quantitatively dilute it to make a solution containing 0.08mg and 0.04mg per 1mL respectively as the reference substance solution; take an appropriate amount of tetracycline hydrochloride reference substance, accurately weigh it, add 0.01mol / L hydrochloric acid solution to dissolve it and quantitatively dilute it to make a solution containing 1μg per 1mL as the reference substance solution (1).

[0064] If there are impurity peaks in the chromatogram of the test solution, the 4-epi-chlortetracycline content shall not exceed 4.0% and the tetracycline hydrochloride content shall not exceed 8.0% according to the peak area calculated by the external standard method. The total amount of other impurities shall not exceed 1.5% according to the external standard method based on 4-epi-chlortetracycline. The chromatographic peaks in the test sample that are smaller than the main peak area of ​​the reference solution (1) can be ignored.

[0065] Part 1 Storage Performance at 40°C

[0066] For specific experimental parameters and result data, please refer to Table 1:

[0067] Table 1

[0068]

[0069] It should be noted that:

[0070] 1. The added concentration of chlortetracycline hydrochloride in Examples 1 to 9 is 20%; the added concentration of chlortetracycline hydrochloride in Examples 10 to 12 is 10%, 40%, and 50%;

[0071] 2. The above ratios are all weight ratios;

[0072] 3. Examples 13 to 15 all used an antioxidant, wherein the antioxidant was thioglycerol; the amount of the antioxidant used was 0.2 wt %.

[0073] Result analysis:

[0074] 1. Propylene glycol and glycerol are better than glycerol formal whether used alone or in combination. These two solvents can effectively inhibit the degradation of chlortetracycline hydrochloride;

[0075] 2. There is no significant difference between the use of propylene glycol and glycerol alone and the use of propylene glycol and glycerol in combination;

[0076] 3. Whether antioxidants are used in the solvent has no substantial effect on the results.

[0077] Part 2 Storage Performance at 60°C

[0078] For specific experimental parameters and result data, please refer to Table 2:

[0079] Table 2

[0080]

[0081] It should be noted that:

[0082] 1. The added concentration of chlortetracycline hydrochloride in Examples 16 to 24 is 20%; the added concentration of chlortetracycline hydrochloride in Examples 25 to 27 is 10%, 40%, and 50%;

[0083] 2. The above ratios are all weight ratios;

[0084] 3. Examples 28 to 34 all use an antioxidant, which is thioglycerol; the amount of the antioxidant used is 0.2 wt%. Examples 35 to 37 all use an antioxidant, which is vitamin E; the amount of the antioxidant used is 0.2 wt%. Examples 38 to 40 all use an antioxidant, which is BHT (2,6-di-tert-butyl-4-methylphenol), and the amount of the antioxidant used is 0.2 wt%.

[0085] Result analysis:

[0086] 1. Referring to Examples 16 to 19, different from the storage conditions at 40°C, propylene glycol and glycerol alone are better than glycerol formal;

[0087] Referring to Examples 16 to 18 and 20 to 27, propylene glycol and glycerol alone are generally inferior to propylene glycol and glycerol mixed;

[0088] 2. With reference to Examples 18, 24, 16, and 19 to 23, the performance of the mixture of propylene glycol and glycerol formal is not as good as that of glycerol formal alone; the performance of the mixture of propylene glycol and glycerol is better than that of glycerol alone in most cases;

[0089] It can be concluded that the compounding objects of propylene glycol are very limited. If propylene glycol is to be used in the form of a mixed solvent, it is best combined with glycerin.

[0090] 3. The discussion on antioxidants is divided into the following parts:

[0091] Thioglycerol: It can be seen from Examples 16, 17, 28 and 29 that thioglycerol has no obvious effect on reducing the degradation of chlortetracycline hydrochloride in a single solvent; it can be seen from Examples 19 to 23 and 30 to 34 that thioglycerol has a certain obvious effect on reducing the degradation of chlortetracycline hydrochloride in a composite solvent, among which the effect is most significant when glycerol: propylene glycol = 4:1, glycerol: propylene glycol = 1:9, and glycerol: propylene glycol = 1:4;

[0092] It can be seen from Examples 35 to 40 that among other antioxidants, vitamin E has a more significant effect in reducing the degradation of chlortetracycline hydrochloride in a composite solvent, while BHT has a negative effect.

[0093] 4. Questions about data accuracy

[0094] In the test items in Table 1 and Table 2, 5d or 10d often appears better than 0d. This is due to data measurement errors. However, the data in Table 1 and Table 2 can truly show the data development trend.

[0095] Part III Dilution Stability

[0096] 3.1 Dilution stability test at different concentrations

[0097] A 20 wt % chlortetracycline hydrochloride suspension (solvent: glycerol, propylene glycol in a weight ratio of 1:1) was prepared according to the above method, and diluted with water to 0.1 g / L, 0.3 g / L, 1 g / L, 1.5 g / L, and 160 g / L to obtain a series of dilutions;

[0098] The above dilution was left to stand at room temperature for 2 hours, and the concentration of chlortetracycline hydrochloride was tested. The results are shown in Table 3:

[0099] Table 3 Concentration test results of different dilution concentrations

[0100] 0.1g / L 0.3g / L 1g / L 1.5g / L 160g / L 0h 0.103 0.314 0.108 1.542 166.868 2h 0.104 0.314 0.108 1.542 166.729

[0101] Result analysis:

[0102] It can be seen from the above results that the prescription of the present invention can be stably present in aqueous solution;

[0103] The reason why this scheme is designed for 2 hours is that during the feeding process, the time from dilution of drinking water to the time when the animals finish drinking it generally does not exceed 2 hours. The above experiment is mainly used to simulate the stability of drugs under normal breeding conditions.

[0104] 3.2 Dilution stability test of the same concentration in different solvents

[0105] According to the formula in Table 4, a series of chlortetracycline hydrochloride suspensions were prepared;

[0106] Table 4 Prescriptions of chlortetracycline hydrochloride suspension prepared with different solvents (the proportions of solvents are all weight ratios)

[0107] Chlortetracycline hydrochloride concentration wt% Solvents Prescription 2 20 glycerin Prescription 3 20 Propylene glycol Prescription 4 20 Glycerin: Propylene glycol = 1:9 Prescription 5 20 Glycerin: Propylene glycol = 9:1 Prescription 6 40 Glycerin: Propylene glycol = 1:9 Prescription 7 10 Glycerin: Propylene glycol = 9:1 Prescription 8 20 Glycerin formal Prescription 9 20 Glycerol formal: propylene glycol = 1:4 Prescription 10 20 Thioglycerol + [Glycerol: Propylene glycol = 1:1]

[0108] According to the concentration of 0.3 g / L, water was used for dilution to obtain the results shown in Table 5. The specific results are shown in Table 5:

[0109] Table 5 Concentration test results of different prescriptions

[0110] Prescription 2 Prescription 3 Prescription 4 Prescription 5 Prescription 6 Prescription 7 Prescription 8 Prescription 9 Prescription 10 0h 3.360 3.351 3.197 3.049 3.202 3.201 3.087 3.292 3.052 2h 3.358 3.349 3.194 3.042 3.210 3.222 3.083 3.285 3.032

[0111] Figure 5 These are photos of chlortetracycline hydrochloride solutions of different dilutions of prescription 1 at 0h;

[0112] Figure 6 These are photos of chlortetracycline hydrochloride dilutions of different dilutions of prescription 1 at 2 hours;

[0113] Figure 7 This is a photo of the chlortetracycline hydrochloride dilution solution of 0.3g / L dilution concentration of prescription 2-10 at 0h;

[0114] Figure 8 This is a photo of the 0.3g / L dilution concentration of chloramphenicol hydrochloride of prescription 2-10 after 2 hours.

[0115] Result analysis:

[0116] 1. From the results in Table 5, it can be seen that each formulation has high stability. Even formulations 8-10, which were not ideal in the high and room temperature storage experiments, still performed acceptable in the dilution experiment.

[0117] 2. Although the experimental performance of prescriptions 8-10 is acceptable, the performance of prescriptions 9 and 10 is relatively poor compared to prescriptions 2-7.

[0118] Combining the results of Tables 1 to 5 above, we can roughly draw the following conclusions:

[0119] 1. The solvent combination of the present invention performs well under high temperature conditions;

[0120] 2. The contribution of antioxidants to the control of the degradation of chlortetracycline hydrochloride is relatively weak;

[0121] 3. After the suspension of the present invention is diluted in any proportion, it can maintain high stability within the expected feeding time.

Claims

1. A chlortetracycline hydrochloride suspension, characterized in that: It is composed of chlortetracycline hydrochloride and a solvent; The solvent is a mixture of glycerol and propylene glycol; The weight ratio of glycerol to propylene glycol in the solvent is 1-9:1-9.

2. The chlortetracycline hydrochloride suspension according to claim 1, characterized in that The concentration of chlortetracycline hydrochloride in the suspension is 1 to 60 wt %.

3. The chlortetracycline hydrochloride suspension according to claim 2, characterized in that: The concentration of chlortetracycline hydrochloride in the suspension is 10-50 wt %.

4. The chlortetracycline hydrochloride suspension according to claim 1, characterized in that: The weight ratio of glycerol to propylene glycol in the solvent is 1-4:1-4.

5. A chlortetracycline hydrochloride suspension, characterized in that: It is composed of chlortetracycline hydrochloride, solvent and antioxidant; The solvent is a mixture of glycerol and propylene glycol; The weight ratio of glycerol to propylene glycol in the solvent is 1-9:1-9.

6. The chlortetracycline hydrochloride suspension according to claim 5, characterized in that: The amount of the antioxidant is 0.001-1 wt %.

7. The chlortetracycline hydrochloride suspension according to claim 5, characterized in that: The antioxidant is one or more of vitamin E, vitamin C, thioglycerol, 2,6-di-tert-butyl-p-cresol, and butylated hydroxyanisole.

8. The chlortetracycline hydrochloride suspension according to claim 5, characterized in that: The concentration of chlortetracycline hydrochloride in the suspension is 1 to 60 wt %.

9. The chlortetracycline hydrochloride suspension according to claim 8, characterized in that: The concentration of chlortetracycline hydrochloride in the suspension is 10-50 wt %.

10. The chlortetracycline hydrochloride suspension according to claim 5, characterized in that: The weight ratio of glycerol to propylene glycol in the solvent is 1-4:1-4.

11. A method for preparing a chlortetracycline hydrochloride suspension according to any one of claims 1 to 4, characterized in that: Put the chlortetracycline hydrochloride raw material into the solvent, grind and stir.

12. The method for preparing aureomycin hydrochloride suspension according to claim 11, characterized in that: Put the chlortetracycline hydrochloride raw material into the solvent, ultrasonicate it, then add the grinding medium, stir it and filter it.

13. A method for preserving chlortetracycline hydrochloride, characterized in that: The chlortetracycline hydrochloride is prepared into the chlortetracycline hydrochloride suspension as claimed in any one of claims 1 to 10 for storage.

14. The storage method according to claim 13, characterized in that: The storage temperature is 0 ~ 80℃.

15. The storage method according to claim 13, characterized in that: The storage temperature is room temperature ~ 60℃.

16. A method for diluting chlortetracycline hydrochloride, characterized in that: The chlortetracycline hydrochloride suspension according to any one of claims 1 to 10 is dispersed in water to obtain a diluted aqueous solution.

17. The dilution method according to claim 16, characterized in that: When the concentration of chlortetracycline hydrochloride in the diluted aqueous solution is 10 mg / mL, a uniform solution can be formed in water; When the content of chlortetracycline hydrochloride in the diluted aqueous solution is higher than 10 mg / mL, the aqueous solution is further mixed with additional water in any ratio.

18. A chlortetracycline hydrochloride diluent, characterized in that: The chlortetracycline hydrochloride suspension as claimed in any one of claims 1 to 10 is dispersed in water in any proportion.